Borislava Mihaylova

• A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease.

  Schlackow I. et al, (2017), Heart

• Body mass index and healthcare costs: a systematic literature review of individual participant data studies.

  Kent S. et al, (2017), Obes Rev, 18, 869 - 879

• The INVEST project: investigating the use of evidence synthesis in the design and analysis of clinical trials.

  Clayton GL. et al, (2017), Trials, 18

• Cholesterol- and blood-pressure-lowering drug use for secondary cardiovascular prevention in 2004-2013 Europe.

  Achelrod D. et al, (2017), Eur J Prev Cardiol, 24, 426 - 436

• Quantifying and Valuing Community Health Worker Time in Improving Access to Malaria Diagnosis and Treatment.

  Castellani J. et al, (2016), Clin Infect Dis, 63, S298 - S305

• Impact of Improving Community-Based Access to Malaria Diagnosis and Treatment on Household Costs.

  Castellani J. et al, (2016), Clin Infect Dis, 63, S256 - S263

• Are statins useful in patients with advanced chronic kidney disease? - Authors' reply.

  Herrington WG. et al, (2016), Lancet Diabetes Endocrinol, 4, 971 - 972

• Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.

  Cholesterol Treatment Trialists' (CTT) Collaboration None. et al, (2016), Lancet Diabetes Endocrinol, 4, 829 - 839

• Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.

  Kent S. et al, (2016), Circ Cardiovasc Qual Outcomes, 9, 348 - 354

• Protocol for analyses of adverse event data from randomized controlled trials of statin therapy.

  Cholesterol Treatment Trialists' (CTT) Collaboration None., (2016), Am Heart J, 176, 63 - 69

• Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).

  Mihaylova B. et al, (2016), Am J Kidney Dis, 67, 576 - 584

• The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review.

  Morton RL. et al, (2016), Nephrol Dial Transplant, 31, 46 - 56

• Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD.

  Morton RL. et al, (2016), Am J Kidney Dis, 67, 31 - 39

• IMPACT OF EDUCATIONAL ATTAINMENT ON HEALTH OUTCOMES IN MODERATE-TO-SEVERE CHRONIC KIDNEY DISEASE

  Morton RL. et al, (2015), NEPHROLOGY DIALYSIS TRANSPLANTATION, 30

• What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?

  Kent S. et al, (2015), BMC Nephrol, 16

• Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.

  Cholesterol Treatment Trialists' (CTT) Collaboration None. et al, (2015), Lancet, 385, 1397 - 1405

• The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84).

  Alva ML. et al, (2015), Diabet Med, 32, 459 - 466

• Out-of-pocket costs and other determinants of access to healthcare for children with febrile illnesses: a case-control study in rural Tanzania.

  Castellani J. et al, (2015), PLoS One, 10

• The effect of diabetes complications on health-related quality of life: the importance of longitudinal data to address patient heterogeneity.

  Alva M. et al, (2014), Health Econ, 23, 487 - 500

• Authors' reply

  Mihaylova B. et al, (2012), The Lancet, 380, 1817 - 1818

• The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.

  Cholesterol Treatment Trialists' (CTT) Collaborators None. et al, (2012), Lancet, 380, 581 - 590

• Review of statistical methods for analysing healthcare resources and costs.

  Mihaylova B. et al, (2011), Health Econ, 20, 897 - 916

• Cost-effectiveness of pre-referral antimalarial, antibacterial, and combined rectal formulations for severe febrile illness.

  Buchanan J. et al, (2010), PLoS One, 5

• RECTAL AND INTRAVENOUS ARTESUNATE FOR SEVERE MALARIA: MODELLING THE IMPACT OF ARTEMISININ RESISTANCE

  Maude RJ. et al, (2010), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 83, 377 - 377

• Estimating the quality of life impact of diabetes related complications: new results from the UKPDS

  Alva ML. et al, (2010), DIABETOLOGIA, 53, S52 - S52

• Cost-effectiveness of duloxetine: the Stress Urinary Incontinence Treatment (SUIT) study.

  Mihaylova B. et al, (2010), Value Health, 13, 565 - 572

• Statin cost-effectiveness in the United States for people at different vascular risk levels.

  Heart Protection Study Collaborative Group None., (2009), Circ Cardiovasc Qual Outcomes, 2, 65 - 72

• Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.

  Briggs A. et al, (2007), Heart, 93, 1081 - 1086

• Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.

  Heart Protection Study Collaborative None. et al, (2006), BMJ, 333

• The cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study

  Briggs A. et al, (2006), HEART, 92, A36 - A36

• Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial

  Mihaylova B. et al, (2005), CIRCULATION, 112, U900 - U901

• Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.

  Mihaylova B. et al, (2005), Lancet, 365, 1779 - 1785

• Economic evaluation of the Heart Protection Study

  Briggs A. et al, (2003), CIRCULATION, 108, 776 - 776

• Clinical effectiveness and cost-effectiveness of growth hormone in adults in relation to impact on quality of life: a systematic review and economic evaluation.

  Bryant J. et al, (2002), Health Technol Assess, 6, 1 - 106

• Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation.

  Bryant J. et al, (2002), Health Technol Assess, 6, 1 - 168

• Hospital costs in relation to body mass index in 1.1 million women in England: a prospective cohort study

  Kent S. et al, Lancet Public Health

Recent Publications

• A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease.

  Schlackow I. et al, (2017), Heart

• Body mass index and healthcare costs: a systematic literature review of individual participant data studies.

  Kent S. et al, (2017), Obes Rev, 18, 869 - 879

• The INVEST project: investigating the use of evidence synthesis in the design and analysis of clinical trials.

  Clayton GL. et al, (2017), Trials, 18

• Cholesterol- and blood-pressure-lowering drug use for secondary cardiovascular prevention in 2004-2013 Europe.

  Achelrod D. et al, (2017), Eur J Prev Cardiol, 24, 426 - 436

• Quantifying and Valuing Community Health Worker Time in Improving Access to Malaria Diagnosis and Treatment.

  Castellani J. et al, (2016), Clin Infect Dis, 63, S298 - S305